. Pharma companies marketing medicines made by third parties in India shall be liable for any quality issues as per CDSCO

  • Institute of Good Manufacturing Practices India
  • Global accredited training & certification provider
  • Approved by Quality Council of India (QCI) & Accredited Vocational Institution of Ministry of HRD, Government of India
  • Approved Training Institute of Food Safety and Standards Authority of India (FSSAI)
  • Recognized by Department of Industrial Policy & Promotion, Ministry of Commerce & Industry, Government of India
  • An ISO 9001:2015 Certified Organisation registered under The Societies Registration Act,1860 Government of India
  • Empanelled under Ministry of Horticulture and Food Processing, Government of Uttar Pradesh
  • Affiliated with Life Sciences and Food Industry Sector Skills Council (SSC) set up by National Skill Development Corporation (NSDC)
  • Conferred with QUALITY COUNCIL OF INDIA (QCI) – D.L. SHAH NATIONAL QUALITY AWARD & ASSOCHAM Services Excellence Award 2017

Trusted by organizations & training participants in over 30 countries
Training | Certification | Education | Research


Pharma companies marketing medicines made by third parties in India shall be liable for any quality issues as per CDSCO

A proposal was approved by The Drugs Technical Advisory Board (DTAB) recently to amend the Drugs & Cosmetics Act to make pharmaceutical marketing firms accountable for any violations of the regulations which means that companies marketing medicines in India will soon be as liable as the manufacturers for any violations of drug regulations that could lead to spurious or substandard medicines.

The proposal would allow checking quality issues in medicines consumed by patients which in turn will help the country’s drug regulator to penalize firms marketing medicines in cases where the medicines are found to have violated the regulations. Punishment includes 3-5 years imprisonment for medicines found not of standard quality by regulators or life imprisonment in cases where the medicines are found spurious.

Approval by DTAB would enable the health ministry to amend the regulations and in turn it will make the regulations applicable to companies listed as marketers on the labels and packaging of these drugs as previously in the absence of proper legislation if a violation happens to the quality of the product then only action is taken against the manufacturer. The proposal would lead to marketing companies taking more precautions ensuring facilities and manufacturing processes as per GMP.